In this work, we analyzed the association between RUNX1 gene expression and the accessibility of BCR3, one of RUNX1 gene breakpoint regions involved in the chromosomal translocation (8;21), a frequent translocation in treatment-related acute myeloid leukemia patients. To this end, we evaluate DNA damage generation induced by in vitro etoposide treatment of KG-1 and Colo320 cells. Our results show that treatment using clinical doses of etoposide for 24 h induces the generation of DNA double strand breaks in the BCR3 of RUNX1 gene in KG-1 cells, but not in Colo320 cells, even though both cell lines express RUNX1 gene. These findings suggest that chromatin accessibility and DNA damage generation at the BCR3 due to treatment with etoposide, is independent of RUNX1 gene expression.
Introduction
Etoposide is a drug used as chemotherapeutic treatment for cancer patients. Its main effect is the induction of DNA double strand breaks (DSBs) along the genome, through the inhibition of the enzyme topoisomerase II ligase activity [1] ; which results in apoptosis of rapidly dividing cells, such as cancer cells. However, etoposide affects normal cells in the body as well, giving rise to side effects. One of the most severe is the development of treatment-related acute myeloid leukemia (t-AML), which affects about 10% of patients, 2-3 years post-treatment [2] . To date, it is unknown what determines that t-AML is the only type of cancer developed as a side effect of treatment with etoposide, as well as the contribution of etoposide to the onset of t-AML.
t-AML is a type of blood cancer associated with a number of genomic aberrations. One of the most frequent in patients is the chromosomal translocation (8;21), in which the genes RUNX1 and ETO recombine. The chromosomal breakpoints of RUNX1 gene involved in the t(8;21) were mapped to the intron 5 of the gene, and designated as breakpoint cluster regions (BCRs): BCR1, BCR2 and BCR3 [3] . In myeloid cells, the BCR3 presented DNaseI hypersensitivity [3] , a feature that suggests an increased chromatin accessibility of that region in that particular cell type. The expression of RUNX1 gene in myeloid cells is key for correct hematopoiesis, thus it is possible that chromatin accessibility in RUNX1 locus may be related to the expression of RUNX1 mRNA.
Therefore, in this study our aim is to determine if treatment with clinical doses of etoposide for 24 h induces the generation of DSBs in the BCR3 of RUNX1 gene, in cells that express RUNX1 gene, using qPCR to assess DSB generation in that specific region.
Materials and methods
Cell lines. KG-1 cells were cultured in IMDM medium, supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin-streptomycin; and Colo320 cells were cultured in RMPI 1640 medium, supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin-streptomycin. All cells were maintained at 37°C, with 5% CO 2 .
RUNX1 mRNA detection. RUNX1 mRNA was detected by RT-PCR and quantitative real-time PCR (qPCR), using as template cDNA synthesized from total RNA (4 µg 
Results and discussion
In this study, we adressed the posibility that the expression of RUNX1 gene could be associated with a higher probability of DSB generation at the BCR3. To test that hypothesis, we treated KG-1 (myeloid) and Colo320 (colon) cells with clinical concentrations of etoposide (18 and 36 mg/L) for 0 and 24 h, and DNA DSB generation at the BCR3 was assessed performing qPCR. Our results show that, although both cell types expressed RUNX1 gene (Fig. 1A, top panel,  Fig. 1B) , after 24 h of etoposide treatment only KG-1 cells presented a statistically significant decrease of the BCR3 region relative amplification with 36 mg/L etoposide ( Fig. 2A, right panel) . These results indicate that DNA DSBs ocurred only in myeloid KG-1 cells, which suggests that RUNX1 gene expression is not correlated to DNA DSB generation in the BCR3 of RUNX1 due to treatment with etoposide. A possible explanation is that chromatin in the BCR3 in myeloid cells could be more accessible than in other cell types, not necessarily as results of RUNX1 expression. For instance, DNase-seq data of hematopoietic cell lines available in the ENCODE Project server reveals colocalization of DNaseI hypersensitivity hotspots with the BCR3 in myeloid cells (Supplementary Figure 1) . As well, it has been previously described that in HL-60 cells, the region BCR3 presents acetylated histone H3 [4] , an epigenetic mark associated with a more relaxed chromatin state [5] . Performing a complete characterization of RUNX1 intron 5 could provide answers about other genomic features within intron 5 that might determine an increased probability of DSB generation in myeloid cells.
These results also provide new insights on the effects of etoposide treatment in cells, showing how it affects one of the chromosomal breakpoints of RUNX1 gene. This type of damage could be one of the initial steps towards t(8;21) generation and subsequent leukemic transformation of myeloid cells due to treatment with etoposide. In conclusion, our results show that, although both KG-1 and Colo320 cell lines express RUNX1 gene at comparable levels, etoposide treatment induced DSB generation only in KG-1 (myeloid) cells, and not in Colo320 (colon) cells, suggesting that the BCR3 of RUNX1 intron 5 is more prone to DSBs in myeloid cells, independent of RUNX1 gene expression. 
